Business Description
CSPC Pharmaceutical Group Ltd
ISIN : HK1093012172
Compare
Compare
Traded in other countries / regions
01093.Hong KongCSPCY.USACVG.Germany1093.Mexico IPO Date
2021-08-17Description
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.75 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 151 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5 | |||||
| Beneish M-Score | -1.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.4 | |||||
| 3-Year EBITDA Growth Rate | 3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.6 | |||||
| 3-Year FCF Growth Rate | -25.6 | |||||
| 3-Year Book Growth Rate | 11.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.54 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 1.03 | |||||
| Days Inventory | 125.04 | |||||
| Days Sales Outstanding | 70.76 | |||||
| Days Payable | 114.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.3 | |||||
| 3-Year Dividend Growth Rate | 12.8 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 6.2 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.59 | |||||
| Operating Margin % | 21.09 | |||||
| Net Margin % | 17.02 | |||||
| FCF Margin % | 7.32 | |||||
| ROE % | 15.49 | |||||
| ROA % | 11.22 | |||||
| ROIC % | 20.68 | |||||
| ROC (Joel Greenblatt) % | 54.09 | |||||
| ROCE % | 18.21 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.06 | |||||
| Forward PE Ratio | 11.98 | |||||
| PE Ratio without NRI | 10.06 | |||||
| Shiller PE Ratio | 8.1 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 1.71 | |||||
| PB Ratio | 1.5 | |||||
| Price-to-Tangible-Book | 1.61 | |||||
| Price-to-Free-Cash-Flow | 22.65 | |||||
| Price-to-Operating-Cash-Flow | 12.42 | |||||
| EV-to-EBIT | 6.4 | |||||
| EV-to-Forward-EBIT | 6.52 | |||||
| EV-to-EBITDA | 6.4 | |||||
| EV-to-Forward-EBITDA | 6.18 | |||||
| EV-to-Revenue | 1.38 | |||||
| EV-to-Forward-Revenue | 1.51 | |||||
| EV-to-FCF | 18.38 | |||||
| Price-to-Projected-FCF | 0.72 | |||||
| Price-to-DCF (Earnings Based) | 0.47 | |||||
| Price-to-DCF (FCF Based) | 1.08 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.63 | |||||
| Price-to-Graham-Number | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 3.88 | |||||
| Earnings Yield (Greenblatt) % | 15.63 | |||||
| FCF Yield % | 4.57 | |||||
| Forward Rate of Return (Yacktman) % | 20.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CSPC Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 75,222.309 | ||
| EPS (TTM) (MXN) | 1.076 | ||
| Beta | -0.31 | ||
| Volatility % | 3.17 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 15.69 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 15.69 - 15.69 | ||
| Shares Outstanding (Mil) | 11,488.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CSPC Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CSPC Pharmaceutical Group Ltd Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
CSPC Pharmaceutical Group Ltd Frequently Asked Questions
What is CSPC Pharmaceutical Group Ltd(MEX:1093)'s stock price today?
The current price of MEX:1093 is MXN15.69. The 52 week high of MEX:1093 is MXN15.69 and 52 week low is MXN15.69.
When is next earnings date of CSPC Pharmaceutical Group Ltd(MEX:1093)?
The next earnings date of CSPC Pharmaceutical Group Ltd(MEX:1093) is 2025-03-20 Est..
Does CSPC Pharmaceutical Group Ltd(MEX:1093) pay dividends? If so, how much?
CSPC Pharmaceutical Group Ltd(MEX:1093) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers